In addition, the use of biomarker-driven approaches to identify the patients most likely to benefit from Src inhibition is critical for optimizing clinical outcomes, providing a promising opportunity in cancer treatment with targeted therapeutic approaches to hinder key pathways driving the growth and metastasis of tumors [91]. Here, SRC is linked to cancer.